Payment overview · 2025
General Payments
$472.00
6 reported records · 3 companies
Healthcare provider profile · identity verified
Bernard A. Stupski, D.O.
Allopathic & Osteopathic Physicians|General Practice · VANCOUVER, WA · NPI 1750571238
Verified facts
What the public records show
CMS Open Payments records show Bernard A. Stupski, D.O. received $472.00 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.00 | 53.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $204.75 | 43.4% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.25 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.05 | 5 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $154.80 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 167 | 52 |
| Gabapentin | Gabapentin | 93 | 19 |
| Lisinopril | Lisinopril | 80 | 27 |
| Omeprazole | Omeprazole | 76 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 63 | 23 |
| Losartan Potassium | Losartan Potassium | 58 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 14 |
| Metformin Hcl | Metformin Hcl | 53 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 45 | 11 |
| Carvedilol | Carvedilol | 44 | 12 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 11 |
| Naproxen | Naproxen | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 20 |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 34 | 11 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Furosemide | Furosemide | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Meloxicam | Meloxicam | 31 | 12 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butrans | Buprenorphine | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $472.00 · 6 records | ABBVIE INC. | Biktarvy, CREON, FREESTYLE INSULINX, FREESTYLE LIBRE 3, LINZESS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error